MVP ASX Week ended 24 Jul 2026

Weekly Investor Report

Name: MVP weekly investor report
Creator: Sharemaestro
License: https://sharemaestro.com/data-license/

Medical Developments International Limited · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data

Latest close 0.50 AUD

22.0% latest week

Weekly setup

Mixed setup

The weekly trend is not active. Price is 13.3% above the Trend Line and sits at 33.8% of its 52-week range. The latest completed week returned 22.0%, after a 28.2% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 60/100.

Setup score 49 out of 100

Latest Close 0.50 AUD 24 Jul 2026

1W Return 22.0% latest completed week

4W Return 28.2% short-term follow-through

12W Return 5.3% quarterly tape

Trend Breadth 17.3% 9 of 52 weeks active

Volume Ratio 3.5x vs 13-week average

What is working

Price is above the Trend Line, keeping the weekly tape constructive.
Activity pressure is positive on the latest completed week.
Volume is elevated versus the 13-week average, confirming attention.
Latest weekly return ranks in the strongest part of its sector group.

What could go wrong

The trend backdrop is inactive, so price action has not confirmed a constructive regime.
Price is below Fair Value, so the market is still discounting the latest tape.
Next-week expectancy is negative at 38.01% based on similar historical setup states.
Activity pressure is weak, so confirmation is not yet broad enough.

What to watch next

Trend Line remains the key weekly regime level.
Activity pressure is the gauge to monitor for confirmation or fade.
A volume ratio above 1.5x would show stronger participation in the next move.

Price follow-through 22.0% Latest completed week; four-week move 28.2%. Indicator stack 10/78 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 38.01% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 60/100 13 relevant articles in the latest sentiment read.

01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 13.3% above the Trend Line and sits at 33.8% of its 52-week range. The latest completed week returned 22.0%, after a 28.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value

Price Trend Line Fair Value

Position in the 52-week range

Close Trend Fair

0.36 AUD 33.8% 0.77 AUD

Range location33.8%Shows where the latest close sits between the 52-week low and high.

Trend distance13.3%Price premium or discount versus the weekly Trend Line.

Fair-value gap-15.0%Premium demand or model discount versus Sharemaestro Fair Value.

High-water gap-34.6%Distance from the latest 52-week high.

02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 3.5x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction

30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul

Up week Down week

Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0812-week average 0.12

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.

Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.

Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.

Activity pressure0.08Current proprietary activity-pressure read.

Buy signals4Accumulation signal count in the latest 12 weeks.

Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 28.2% over four weeks, 5.3% over 12 weeks, and -23.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W22.0%

4W28.2%

12W5.3%

26W0.0%

52W-23.1%

Active trend streak0 weeks

Active weeks in one year9

Trend breadth17.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership

Pressure0.72Latest activity-pressure read.

Pressure change191.7%Four-week change in activity pressure.

Leadership-2.48Latest relative-leadership reading.

RS change90.5%Four-week change in relative leadership.

04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis

Factor week 26 Jul 2026 Financial statements through 30 Jun 2025 Field coverage 76% Model confidence 40%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength5/100Blend of value, momentum, and quality. Underlying universe rank 96; rank 1 is best.

Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.

Quality12/100Profitability and accounting quality. Underlying universe rank 89; rank 1 is best.

Momentum8/100Medium-term price momentum. Underlying universe rank 93; rank 1 is best.

Growth89/100Revenue and earnings growth. Underlying universe rank 12; rank 1 is best.

How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E: 599.2x
Price / sales: 1.4x
EV / EBITDA: 11.7x
Free-cash-flow yield: -2.7%

Business quality

Margins and the return generated on invested capital.

Gross margin: 75.3%
Operating margin: -4.5%
Free-cash-flow margin: -2.8%
Return on invested capital: -3.4%

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth: 17.8%
EPS growth: -
Free-cash-flow growth: -
Piotroski F-score: 6/9

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield: -
Buyback yield: -15.9%
Shareholder yield: -15.9%
Net debt / EBITDA: -4.6x

05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment60/100

Weighted news tone is neutral across 13 relevant articles.

5 positive · 8 neutral · 0 negative

Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks

06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.

Options expected move-Nearest-chain priced movement where available.

52-week drawdown-34.6%Distance below the 52-week high.

13-week volatility8.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

30 Jan 27 Feb 27 Mar 24 Apr 22 May 19 Jun 24 Jul

Weeks higher10 of 2616 weeks finished lower.

Best week+38.7%Week of 24 Apr.

Worst week-9.6%Week of 17 Apr.

Latest week+22.0%Week of 24 Jul.

Shape of recent returns

Strong gains5

Modest gains5

Flat weeks0

Modest losses6

Sharp losses10

Recent vol8.0%13-week weekly-return volatility.

Base vol9.4%52-week weekly-return volatility.

Up/down split20/31Count of positive and negative weeks in the 52-week window.

Average skew8.0% / -5.4%Average positive week versus average negative week.

07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

SectorAU Healthcare

4-week rank9 / 100

Group average1.9%

Trend breadth22.0%

Trend22.0%active weekly trend signals

MD60.0%positive activity pressure

RS29.0%positive relative leadership

Four-week leaders

PTX · ASX50.8%PIQ · ASX44.2%VIT · ASX36.4%EZZ · ASX35.5%NEU · ASX34.9%

IndustryAU Drug Manufacturers - Specialty & Generic

4-week rank5 / 16

Group average16.0%

Trend breadth12.5%

Trend12.5%active weekly trend signals

MD62.5%positive activity pressure

RS25.0%positive relative leadership

Four-week leaders

ECS · ASX50.0%VIT · ASX36.4%RGT · ASX35.1%BP8 · ASX33.3%MVP · ASX28.2%

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape40/100

Trend, activity pressure, participation, and risk combine to a 40/100 tape read.

Indicator analysis31/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.08; No reversal markers Next-Week ExpectancyNegative 38.01%

Next-week expectancy is negative with a 38.01% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors9/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 86; Small Cap Core rank 88 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Sentiment60/100

Weighted news tone is neutral across 13 relevant articles.

Medical Developments (ASX:MVP) Achieves Positive Cash Flow on Penthrox Growth Insiders50/100

No recent insider transaction evidence is stored.

Earnings50/100

No stored earnings event is currently attached to this ticker.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
24 Jul 2026	0.50 AUD	22.0%	0.44 AUD	0.59 AUD	0.72	-2.48	2.7M	Off
17 Jul 2026	0.41 AUD	1.2%	0.44 AUD	0.59 AUD	0.42	-20.72	703.0K	Off
10 Jul 2026	0.41 AUD	-2.4%	0.45 AUD	0.60 AUD	0.36	-22.49	198.5K	Off
3 Jul 2026	0.41 AUD	6.4%	0.45 AUD	0.61 AUD	0.30	-21.47	993.4K	Off
26 Jun 2026	0.39 AUD	-6.0%	0.46 AUD	0.61 AUD	0.25	-26.09	886.5K	Off
19 Jun 2026	0.41 AUD	7.8%	0.46 AUD	0.61 AUD	0.15	-22.39	250.5K	Off
12 Jun 2026	0.39 AUD	1.3%	0.46 AUD	0.62 AUD	0.27	-28.26	140.4K	Off
5 Jun 2026	0.38 AUD	-1.3%	0.47 AUD	0.62 AUD	0.40	-28.29	1.3M	Off
29 May 2026	0.39 AUD	-6.1%	0.48 AUD	0.62 AUD	0.37	-28.88	407.7K	Off
22 May 2026	0.41 AUD	-4.7%	0.49 AUD	0.62 AUD	0.61	-24.38	1.1M	Off
15 May 2026	0.43 AUD	-2.3%	0.50 AUD	0.63 AUD	0.69	-21.10	351.6K	Off
8 May 2026	0.44 AUD	-7.4%	0.51 AUD	0.63 AUD	0.31	-20.83	218.6K	Off
1 May 2026	0.47 AUD	-8.7%	0.51 AUD	0.63 AUD	-0.14	-15.09	761.8K	Off
24 Apr 2026	0.52 AUD	38.7%	0.52 AUD	0.63 AUD	-0.64	-8.29	1.4M	Off

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.